Alpine Immune Sciences, Inc.

Equities

ALPN

US02083G1004

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:43:35 2024-04-29 pm EDT			5-day change	1st Jan Change
64.66 ^USD	+0.15%		+0.12%	+239.22%

Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ
Apr. 16	TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy	MT

Health Care Slips on Risk Bias -- Health Care Roundup

April 11, 2024 at 05:18 pm EDT

Health-care companies slipped as a bias for high-risk sectors offset a boost from deal activity.

Vertex Pharmaceuticals agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases, the latest in a wave of health-care deals.

Among other deals in the last couple of months, health-care conglomerate Johnson & Johnson struck a $13.1 billion deal to buy heart-disease device maker Shockwave Medical; Danish biotechnology company Genmab agreed to buy cancer-drug maker U.S. ProfoundBio for $1.8 billion; and Swiss drug maker Novartis agreed to buy MorphoSys for about $2.9 billion.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

04-11-24 1717ET

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
GENMAB A/S	1,970 DKK	+0.79%	-2.96%	18.15B
VERTEX PHARMACEUTICALS INCORPORATED	396.2 USD	-0.33%	-0.95%	103B
SHOCKWAVE MEDICAL, INC.	329.9 USD	-0.02%	+0.50%	12.38B
NOVARTIS AG	88.87 CHF	-0.70%	+1.73%	200B
ALPINE IMMUNE SCIENCES, INC.	64.66 USD	+0.15%	+0.12%	4.24B
MORPHOSYS AG	65.65 EUR	-3.24%	-3.10%	2.73B

Latest news about Alpine Immune Sciences, Inc.

North American Morning Briefing : Stock Futures -2-	Apr. 17	DJ
TD Cowen Downgrades Alpine Immune Sciences to Hold From Buy	Apr. 16	MT
North American Morning Briefing : Stock Futures -2-	Apr. 15	DJ
Leerink Partners Downgrades Alpine Immune Sciences to Market Perform From Outperform	Apr. 12	MT
North American Morning Briefing : Big Banks Kick -2-	Apr. 12	DJ
Health Care Slips on Risk Bias -- Health Care Roundup	Apr. 11	DJ
Wall Street rebounds on softer inflation data, eyes on earnings	Apr. 11	RE
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...	Apr. 11
Wolfe Research Downgrades Alpine Immune Sciences to Peer Perform From Outperform	Apr. 11	MT
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	Apr. 11	MT
Will there be any Fed rate cuts this year?	Apr. 11
Nasdaq set for higher open as fresh inflation data allays rate jitters	Apr. 11	RE
Wholesale Prices Rise Less Than Expected in March as US Equity Futures Waver Pre-Bell	Apr. 11	MT
Sector Update: Health Care	Apr. 11	MT
HC Wainwright Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $50	Apr. 11	MT
Guggenheim Downgrades Alpine Immune Sciences to Neutral From Buy, Raises Price Target to $65 From $55	Apr. 11	MT
Wedbush Downgrades Alpine Immune Sciences to Neutral From Outperform, Raises Price Target to $65 From $47, Expects Vertex Deal to Close	Apr. 11	MT
Top Premarket Gainers	Apr. 11	MT
Vertex Pharmaceuticals' $4.9 Billion Deal for Alpine Shows Lead-Candidate's Potential, Analysts Say	Apr. 11	MT
Morgan Stanley Downgrades Alpine Immune Sciences to Equalweight From Overweight, Raises Price Target to $65 From $47	Apr. 11	MT
News Highlights : Top Company News of the Day - Thursday at 7 AM ET	Apr. 11	DJ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal	Apr. 11	MT
Futures slip as rate-cut hopes ebb	Apr. 11	RE
European Midday Briefing : ECB Expected to Hold Rates, Lagarde Message Key	Apr. 11	DJ

Chart Alpine Immune Sciences, Inc.

Duration

Period

More charts

Company Profile

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Companyâs approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Alpine Immune Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

64.56 USD

Average target price

62 USD

Spread / Average Target

-3.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALPINE IMMUNE SCIENCES, INC.	+239.22%	4.24B
VERTEX PHARMACEUTICALS INCORPORATED	-2.65%	103B
REGENERON PHARMACEUTICALS, INC.	+1.58%	95.28B
ARGENX SE	+1.46%	22.15B
BIONTECH SE	-15.56%	21.02B
GENMAB A/S	-8.58%	18.15B
WUXI APPTEC CO., LTD.	-38.74%	16.73B
BEIGENE, LTD.	-12.96%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+5.18%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.60%	12.17B

Bio Therapeutic Drugs